Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch + Lomb has launched the INFUSE™ silicone hydrogel daily disposable contact lens, designed to combat contact lens dryness affecting about half of U.S. lens wearers. This lens utilizes ProBalance Technology™ to maintain ocular surface homeostasis and retain 96% moisture for 16 hours. The advanced design aims to provide comfort without sacrificing vision correction. Bausch Health Companies Inc. (NYSE/TSX: BHC) emphasizes its commitment to innovative eye care solutions, reflecting the need for advanced materials in contact lens technology.
Bausch Health announced the approval of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses by Health Canada. These lenses incorporate Advanced MoistureSeal® Technology and ComfortFeel Technology, ensuring a high level of comfort and eye health for up to 16 hours. They will be available to select practitioners in Canada starting Q4 2020, with a full launch expected in early 2021. This innovation enhances Bausch + Lomb's existing product portfolio, aiming to improve patient experience in eye care.
Bausch Health reported revenues of $1.664 billion for Q2 2020, a 23% decline from Q2 2019, largely due to the COVID-19 pandemic.
GAAP net loss was $326 million, compared to a $171 million loss in the same quarter last year.
The company has narrowed its full-year revenue guidance to $7.80 - $8.00 billion and Adjusted EBITDA to $3.15 - $3.30 billion.
Despite challenges, Bausch Health is focused on market share growth and launching new products.
Bausch Health Companies Inc. (BHC) announced its plan to spin off its eye health business, creating an independent entity named Bausch + Lomb - NewCo. This strategic move aims to enhance focus on two distinct business segments: a dedicated eye health company and a diversified pharmaceutical firm specializing in gastroenterology, aesthetics/dermatology, and neurology. The spinoff is expected to improve financial transparency and unlock shareholder value. Bausch + Lomb - NewCo reported $3.7 billion in revenue for 2019, while BHC's revenue was $4.9 billion, with plans to report separate financials starting Q1 2021.
Bausch Health (NYSE/TSX: BHC) has resolved a legacy investigation by the SEC concerning its past relationship with Philidor Rx and certain accounting practices from 2014-2015. The settlement, which involves a $45 million civil penalty for negligence-based charges, resolves all SEC claims without admission of guilt. The company has undergone significant management changes, with a new Board of Directors credited for remedial actions. CEO Joseph C. Papa emphasized that this resolution is a crucial step in the company's transformation.
Bausch Health Companies Inc. (NYSE/TSX: BHC) and Ortho Dermatologics announced nine recipients of the 2020 Aspire Higher scholarship program, aimed at supporting students affected by dermatologic conditions. Each recipient will receive up to $10,000 for their education. The program has awarded a total of $738,000 to 51 students since its inception in 2013. The recipients were selected from nearly 220 applications, showcasing their challenges and successes in education. To learn more, visit AspireHigherScholarships.com.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will release its second-quarter 2020 financial results on August 6, 2020, at 8:00 a.m. EDT. The company will host a conference call and live webcast to discuss the results and provide a business update. Interested parties can access the materials on the Investor Relations section of Bausch Health's website prior to the call. A replay of the call will be available until August 20, 2020, with specific dial-in information provided.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that ARAZLO™ (tazarotene) Lotion, 0.045% is now available for the treatment of acne vulgaris in patients aged nine and older. Approved by the FDA in December 2019, ARAZLO offers a lotion formulation known for its lower irritation compared to traditional tazarotene creams. Clinical studies demonstrate efficacy similar to Tazorac with fewer adverse events. ARAZLO is priced comparably to other branded acne treatments, with many patients facing no co-pay through insurance and the access program.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that key executives will participate in the Goldman Sachs Leveraged Finance Conference on June 25, 2020, at 11:25 a.m. EDT. The executives include Paul S. Herendeen, Arthur J. Shannon, and William Woodfield. A live webcast and audio archive will be available on the company’s Investor Relations page. Bausch Health aims to enhance lives through its diverse healthcare products, focusing on eye health, gastroenterology, and dermatology.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the inaugural Salix Gastrointestinal Health Scholars Program, awarding scholarships to ten students living with gastrointestinal diseases. Each recipient will receive $10,000 to support their education. The selection was based on over 100 applications, with an independent panel reviewing essays that highlighted the challenges faced by applicants and the support received from healthcare professionals. The program aims to recognize students' resilience in pursuing academic achievements despite their health challenges.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
